Assessment of higher-order singular value decomposition denoising methods on dynamic hyperpolarized $[1^{-13}C]$pyruvate MRI data from patients with glioma

Sana Vaziri a, Adam W. Autry a, Marisa Lafontaine a, Yaewon Kim a, Jeremy W. Gordon a, Hsin-Yu Chen a, Jasmine Y. Hu a, Janine M. Lupo a, Susan M. Chang b, Jennifer L. Clarke b, Javier E. Villanueva-Meyer a,b, Nancy Ann Oberheim Bush b, Duan Xu b, Peder E.Z. Larson a, Daniel B. Vigneron a, Yan Li a,b,*

a Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, United States
b Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, United States

ARTICLE INFO

Keywords:
Hyperpolarized Carbon-13 Denoising Signal-to-noise ratio Glioma Higher-order singular value decomposition

A B S T R A C T

Background: Real-time metabolic conversion of intravenously-injected hyperpolarized $[1^{-13}C]$pyruvate to $[1^{-13}C]$lactate and $[1^{-13}C]$bicarbonate in the brain can be measured using dynamic hyperpolarized carbon-13 (HP-$^{13}$C) MRI. However, voxel-wise evaluation of metabolism in patients with glioma is challenged by the limited signal-to-noise ratio (SNR) of downstream $^{13}$C metabolites, especially within lesions. The purpose of this study was to evaluate the ability of higher-order singular value decomposition (HOSVD) denoising methods to enhance dynamic HP-$^{13}$C pyruvate MRI data acquired from patients with glioma.

Methods: Dynamic HP-$^{13}$C MRI were acquired from 14 patients with glioma. The effects of two HOSVD denoising techniques, tensor rank truncation-image enhancement (TRI) and global-local HOSVD (GL-HOSVD), on the SNR and kinetic modeling were analyzed in $[1^{-13}C]$lactate data with simulated noise that matched the levels of $[1^{-13}C]$bicarbonate signals. Both methods were then evaluated in patient data based on their ability to improve $[1^{-13}C]$pyruvate, $[1^{-13}C]$lactate and $[1^{-13}C]$bicarbonate SNR. The effects of denoising on voxel-wise kinetic modeling of $k_{PL}$ and $k_{PB}$ was also evaluated. The number of voxels with reliable kinetic modeling of pyruvate-to-lactate ($k_{PL}$) and pyruvate-to-bicarbonate ($k_{PB}$) conversion rates within regions of interest (ROIs) before and after denoising was then compared.

Results: Both denoising methods improved metabolite SNR and regional signal coverage. In patient data, the average increase in peak dynamic metabolite SNR was 2-fold using TRI and 4-5 folds using GL-HOSVD denoising compared to acquired data. Denoising reduced $k_{PL}$ modeling errors from a native average of 23% to 16% (TRI) and 15% (GL-HOSVD); and $k_{PB}$ error from 42% to 34% (TRI) and 37% (GL-HOSVD) (values were averaged voxelwise over all datasets). In contrast-enhancing lesions, the average number of voxels demonstrating within-tolerance $k_{PL}$ modeling error relative to the total voxels increased from 48% in the original data to 84% (TRI) and 90% (GL-HOSVD), while the number of voxels showing within-tolerance $k_{PB}$ modeling error increased from 0% to 15% (TRI) and 8% (GL-HOSVD).

Conclusion: Post-processing denoising methods significantly improved the SNR of dynamic HP-$^{13}$C imaging data, resulting in a greater number of voxels satisfying minimum SNR criteria and maximum kinetic modeling errors in tumor lesions. This enhancement can aid in the voxel-wise analysis of HP-$^{13}$C data and thereby improve monitoring of metabolic changes in patients with glioma following treatment.

Abbreviations: SNR, signal-to-noise ratio; HP, hyperpolarized; HP-$^{13}$C, hyperpolarized carbon-13; HOSVD, higher-order singular value decomposition; TRI, tensor rank truncation-image enhancement; GL-HOSVD, global-local HOSVD; ROI, region of interest; LDH, lactate dehydrogenase; PDH, pyruvate dehydrogenase; QC, quality control; CEI, contrast-enhancing lesion; NEL, non-enhancing lesion; NAWM, normal appearing white matter; aSNR, apparent SNR; AUC, area-under-the-dynamic-curve; MSE, mean squared error.

* Corresponding author at: Department of Radiology and Biomedical Imaging, University of California San Francisco, 185 Berry Street, Ste 350, San Francisco, CA 94107, United States.

E-mail address: yan.li@ucsf.edu (Y. Li).

https://doi.org/10.1016/j.nicl.2022.103155
Received 17 May 2022; Received in revised form 12 August 2022; Accepted 13 August 2022
Available online 17 August 2022
2213-1582/© 2022 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Dynamic hyperpolarized carbon-13 (HP-\(^{13}\)C) MR metabolic imaging is able to non-invasively capture real-time metabolism after injecting a pre-polarized \(^{13}\)C-enriched probe (Ardenkjaer-Larsen et al., 2003). The most commonly used probe, HP [\(^{1-13}\)C]pyruvate, has been extensively evaluated in several human brain studies (Austry et al., 2020b; Grist et al., 2019; Lee et al., 2021a; Lee et al., 2020; Li et al., 2021; Miloushev et al., 2018; Park et al., 2018). The fundamental rationale for its use in brain tumors is the Warburg effect (Golman et al., 2006; Warburg, 1956), which describes the upregulation of glycolytic metabolism by increased lactate dehydrogenase (LDH) expression, with the simultaneous downregulation of oxidative phosphorylation (Schoedel et al., 2009) by way of decreased pyruvate dehydrogenase (PDH) in cancers. Previous studies characterizing brain tumors have shown increased conversion from [\(^{1-13}\)C]pyruvate to [\(^{1-13}\)C]lactate and decreased conversion from [\(^{1-13}\)C]pyruvate to [\(^{13}\)C]bicarbonate in progressive tumor compared to normal-appearing brain tissue (Austry et al., 2020a; Austry et al., 2020b; Park et al., 2018). The relatively low [\(^{13}\)C]bicarbonate signal, particularly in tumors due to metabolic reprogramming, has limited the ability to study oxidative phosphorylation using pyruvate-to-bicarbonate flux modeling (Austry et al., 2020b). In normal-appearing white matter (NAWM) voxels, the signal-to-noise ratio (SNR) of [\(^{13}\)C]bicarbonate data can be as much as 3-fold lower than that of [\(^{1-13}\)C]lactate (Austry et al., 2020b; Grist et al., 2019), which may hinder voxel-wise metabolite analysis for other applications (Grist et al., 2020).

A unique challenge associated with HP-\(^{13}\)C acquisitions lies in the irreversible and rapid decay of the hyperpolarized signal, which translates into limited SNR for measured metabolites following the injection of the tracer. Advances in HP-\(^{13}\)C acquisitions include the optimization of quality control (QC) steps to reduce the time-to-injection (Austry et al., 2020b; Li et al., 2021), using multichannel receiver coils (Austry et al., 2019; Sanchez-Heredia et al., 2020), and development of fast (Gordon et al., 2021) and variable resolution acquisitions for metabolites with different SNRs (Gordon et al., 2020). These advances have provided reliable enhancements for evaluating the human brain.

Post-processing denoising offers another avenue for improving the SNR of HP-\(^{13}\)C data after data acquisition. A breadth of higher-order singular value decomposition (HOSVD) techniques (De Lathauwer et al., 2000; Rajvaid et al., 2013) that can produce up to a 10-fold increase in apparent SNR and have been applied to denoise MR data (Breider et al., 2019; Lee et al., 2021b; Zhang et al., 2017; Zhang et al., 2015). HOSVD denoising methods rely on underlying assumptions of sparsity within the multidimensional data along with the presence of random, Gaussian-distributed noise. Under these conditions, noise reduction can be achieved via truncation of the HOSVD core tensor. Tensor decomposition methods, such as tensor rank truncation-image enhancement (TRI) (Chen et al., 2020), treat the data as a single tensor of spatial and temporal dimensions for denoising and have been applied to HP-\(^{13}\)C MR spectroscopic imaging (MRSI). A patch-based approach, global-local HOSVD (GL-HOSVD), applies a global HOSVD pre-filtering step before grouping similar data patches together and applying a local HOSVD denoising on each patch (Zhang et al., 2017). It has been reported that GL-HOSVD denoising increased the SNR of HP-\(^{13}\)C MRI data acquired from healthy brain volunteers (Kim et al., 2021).

The purpose of this study was to evaluate the ability of the denoising techniques TRI and GL-HOSVD to recover the signals obscured by noise from dynamic HP-\(^{13}\)C MRI of patients with glioma. Simulated low-SNR dynamic metabolite images derived from data acquired from patients were first denoised and compared to the acquired signals. Voxel-wise SNR improvements and the number of voxels with reliable kinetic modeling for [\(^{1-13}\)C]pyruvate, [\(^{1-13}\)C]lactate, and [\(^{13}\)C]bicarbonate were then evaluated within the anatomic lesions and normal-appearing brain.

2. Methods

2.1. Patient population and treatments

A total of 14 patients with adult-type grade 4 diffuse gliomas at different disease status (9 recurrent, 5 newly diagnosed) were involved in this study. Most patients had received a combination of different therapies. The characteristics of the studied patient population are summarized in Table 1. Each patient was given written informed consent in accordance with the University of California San Francisco IRB procedures.

2.2. Imaging protocol

All MR studies were performed using a dual-tuned \(^{13}\)C volume transmit/24-channel receiver and \(^{1}\)H 8-channel receiver head coil (Rapid Biomedical, Germany) on a 3 T scanner (GE Healthcare, Waukesha, WI). The standard-of-care anatomic imaging (Ellingson et al., 2015) consisted of 3D pre- and post-contrast T1-weighted inversion recovery-prepared spoiled gradient echo (IRSPGR) images (repetition time [TR]/echo time [TE]/inversion time [TI] = 8/3/400 ms, slice thickness = 1.5 mm, field of view [FOV] = 25.6 × 25.6 cm, matrix = 256 × 256) and T2-weighted fluid attenuated inversion recovery (FLAIR) images (TR/TE/TI = 6250/138/1702 ms, slice thickness = 1.5 mm, FOV = 25.6 × 25.6 cm, matrix = 256 × 256).

The procedures of obtaining HP [\(^{1-13}\)C]pyruvate MRI included

---

**Table 1**: Clinical patient summary.

| No. | Age | Diagnosis | Disease status at imaging | Treatment Received | Subsequent clinical status |
|-----|-----|-----------|--------------------------|--------------------|--------------------------|
| 1   | 39  | Astrocytoma, IDH-mutant, grade 4 | Recurrent | Sx, RT, TMZ, bevacizumab | Stable |
| 2   | 55  | Glioblastoma, IDH-wildtype  | Newly diagnosed | Sx, RT, TMZ | Stable |
| 3   | 62  | Glioblastoma, IDH-wildtype | Recurrent | Sx, RT, TMZ, DCVax, Oliparib, everolimus, CCNU, bevacizumab | Progressed |
| 4   | 70  | Glioblastoma, IDH-wildtype  | Recurrent | Sx, RT, TMZ, CCNU, Afinlimab | Stable |
| 5   | 63  | Glioblastoma, IDH-wildtype  | Recurrent | Sx, RT, TMZ | Stable |
| 6   | 55  | Glioblastoma, IDH-wildtype | Recurrent | Sx, RT, TMZ, CCNU, Temozolim, Everolimus | Progressed |
| 7   | 51  | Glioblastoma, IDH-wildtype  | Recurrent | Sx, RT, TMZ, DCVax, Toc95PC, bevacizumab | Stable |
| 8   | 58  | Glioblastoma, IDH-wildtype  | Newly diagnosed | RT, TMZ, Optune, CCNU, Afatinib, Acelciblub | Stable |
| 9   | 44  | Glioblastoma, IDH-wildtype  | Recurrent | Sx, RT, TMZ | Stable |
| 10  | 44  | Glioblastoma, IDH-wildtype | Newly diagnosed | Sx, RT, TMZ, BGB-290 | Stable |
| 11  | 45  | Glioblastoma, IDH-wildtype  | Recurrent | Sx, Nivolumab, Poliovirus | Stable |
| 12  | 63  | Glioblastoma, IDH-wildtype  | Recurrent | Sx, RT, TMZ | Stable |
| 13  | 58  | Glioblastoma, IDH-wildtype | Newly diagnosed | None | NA |
| 14  | 55  | Glioblastoma, IDH-wildtype  | Newly diagnosed | None | NA |

Sx = surgery; RT = radiation therapy; TMZ = temozolomide; CCNU = lomustine; DCVax = dendritic cell vaccine; Toca511c = 5-flucytosine; BGB-290 = paminarib.
sample preparation, hyperpolarization using the clinical SPINlab system (General Electric, Niskayuna, NY) and QC prior to injection (Autry et al., 2020b; Li et al., 2021; Park et al., 2018). The median and range values of QC and injection parameters were as follows: polarization = 38.3 [21.4, 46.4] %, pyruvate concentration = 232 [194, 259] (mM), pH = 7.8 [7.4, 8.2], and temperature = 32.0 [29.7, 34.3] °C, and injected pyruvate volume = 33 [24, 40] mL (values = median [min, max]). After on-site pharmacist approval, HP [1-13C]pyruvate was injected intravenously at a dosage of 0.43 mL/kg followed by 20 mL saline (Autry et al., 2020b). Median and range of time-to-injection were = 50 [46, 72] seconds (median [min, max]). The noise-only data was acquired separately prior to the injection.

The frequency reference for [1-13C]pyruvate acquisition was set using the in vivo center frequency of water from a 1H scan together with a conversion factor between H1/13C gyromagnetic ratios: \( f_{\text{13C}} = f_{\text{water}} \times 0.2514918899 \). The dynamic HP-13C scan began 5 s after the end of injection using a frequency-specific multislice echo planar imaging (EPI) sequence (TR/TE = 62.5 ms/21.7 ms, 1032 μs echo-spacing, ±10 kHz BW; 3 frequencies, [1-13C]pyruvate, [1-13C]lactate, [13C]bicarbonate flip angles = 20°, 30°, 30°; FOV = 24.0 \times 24.0 cm; 1.5 cm isotropic spatial resolution, 8 slices; 20 timepoints, 3 s temporal resolution; 60 s total acquisition time) (Autry et al., 2020b; Gordon et al., 2019; Gordon et al., 2017).

2.3. ROI segmentation

All the 1H images were aligned to the corresponding T1-weighted post-contrast images (Li et al., 2011). The masks of T2 hyperintense lesions were segmented on FLAIR images while contrast-enhancing lesions (CEL) were defined from the post-contrast T1 images using 3D Slicer (https://www.slicer.org). Segmentation of white matter was performed on the T1-weighted pre-contrast images using in-house tools (Li et al., 2011; Zhang et al., 2011), and refined by excluding the cortex segmented by the automated anatomical labeling atlas 3 (Rolls et al., 2020) using nonlinear registration (FMRIB Software Library, fsl.fmrib.ox.ac.uk/fsl/fslwiki/FSL). All masks were down-sampled to the spatial resolution of 13C data. Regions of interest (ROIs) were defined at HP-13C resolution and included CEL (voxels comprised of > 20 % contrast-enhancing disease), non-enhancing lesion (NEL; non-enhancing voxels comprised of > 40 % T2 lesion), and normal appearing white matter (NAWM; non-T2 lesion voxels comprised of > 40 % white matter).

2.4. Post-processing of dynamic 13C data

Raw dynamic 13C EPI data from the 24-channel coil were first corrected for Nyquist ghosting artifacts using an exhaustive search (Wang et al., 2018). Prewhitenning to reduce the effects of coil coupling was performed by determining the decorrelation matrix from noise data without HP substrate using Cholesky decomposition (Pruessmann et al., 2001) and then dividing the HP data by this matrix. Coil combination was performed using complex weights from pyruvate data (2hu et al., 2019). Area-under-the-dynamic-curve (AUC) images were calculated for each metabolite by taking the temporal sum of dynamic images. Voxel-wise phase correction was performed separately for each metabolite by estimating the phase from complex AUC images (Crane et al., 2021).

2.5. Metabolic parameters derived from dynamic 13C data

Noise levels for the dynamic data of each metabolite were estimated using the standard deviation of background voxels. Noise levels for the AUC images were estimated by dividing the estimated dynamic noise levels by the square root of the number of time points acquired. Peak dynamic SNR was defined as the maximum dynamic intensity divided by the dynamic noise level. Voxel-wise apparent SNR (aSNR) maps were calculated by dividing phase corrected AUC images by the AUC noise level. SNR masks were created to filter out voxels with aSNR < 5, as these were deemed unreliable.

Voxel-wise apparent rate constants for pyruvate-to-lactate (kPL) and pyruvate-to-bicarbonate (kPB) were quantified from dynamic HP-13C data using an input-less kinetic model (Autry et al., 2020b; Larson et al., 2018; Mammodi et al., 2020). Modeling fit errors were defined as the 95 % confidence interval of the fit (Mammodi et al., 2020). Modeling error masks for kPL and kPB maps were created to filter out voxels with errors >30 % and 50 % of the estimated value, respectively. Signal coverages, or quantifiable regions, were calculated as a percentage of total voxels within each ROI after filtering by SNR mask (%NPyruvate, %NLactate, %NBicarbonate) or modeling error masks (%NLPyruvate, %NLbicarbonate). Ratios of lactate-to-pyruvate, bicarbonate-to-pyruvate, and bicarbonate-to-lactate were calculated from AUC maps after applying SNR masks.

2.6. Data analysis

2.6.1. Denoising parameters

All denoising was performed on the real part of phased dynamic metabolite data. TRI denoising was applied to each metabolite data separately (Chen et al., 2020). The input tensor was the entire dynamic metabolite volume of size 16 \times 16 \times 8 \times 20 (3 spatial dimensions, 1 temporal dimension). The tensor rank was set to 10 \times 10 \times 8 in the spatial dimensions and 4 in the temporal dimension. This value was selected after optimizing for lowest denoised lactate signal mean squared error (MSE) and then increasing the rank in the in-plane spatial dimension based on the smoothing artifacts, size of the imaged brain, and the multi-linear singular values of the input tensor in each dimension. GL-HOSVD denoising (https://github.com/XinyuanZhang719/gl-hosvd) was applied on a slice-by-slice basis to each dynamic metabolite image, as previously described (Kim et al., 2021). The input tensor was of size 16 \times 16 \times 20 (2 spatial, 1 temporal dimension), the patch size was 4 \times 4, and the search window size for finding similar patches was 6 \times 6. After optimizing for lowest lactate signal MSE, the parameter k global was set to 0.4, and k local was set to be between 0.6 and 0.8.

2.6.2. Evaluation of denoising methods using simulations

Zero-mean Gaussian noise was simulated and added to acquired phased dynamic [1-13C]lactate data to match the SNR level of [13C] bicarbonate signals. The resulting signal is referred to as the noise-added data and was then denoised using TRI and GL-HOSVD (hereafter referred to as the noise-added + TRI and noise-added + GL-HOSVD data, respectively). Denoised signals were compared against the acquired signal, although it should be noted that the acquired signal is not noise-free. For each patient dataset, noise level, peak dynamic SNR, SNR masks, kPL values, and kPB modeling errors were calculated for noise-added, noise-added + TRI, and noise-added + GL-HOSVD data. MSE values were computed against the ground truth for dynamic traces and kPL maps restricted to each ROI. Dice scores were calculated comparing SNR masks and modeling error masks to their acquired data counterparts. Two-sample t-tests with a significance level of p-value < 0.05 were performed to compare two denoising methods and determine the significance of SNR and coverage improvements of denoising across all datasets.

2.6.3. Evaluation of denoising on patient data

For each patient dataset, the acquired [1-13C]pyruvate, [1-13C]lactate, and [13C]bicarbonate signals were denoised using TRI and GL-HOSVD. The peak dynamic SNR values, SNR masks, and voxel-wise kPL and kPB maps were calculated using the acquired data, TRI denoised, and GL-HOSVD denoised data. %NPyruvate, %NLactate, %NBicarbonate, %NLPyruvate and %NLbicarbonate were also computed within each ROI for the acquired and denoised data. Two-sample t-tests with a significance level of p-value < 0.05 was performed to compare voxel-wise values between acquired and denoised data, and between two denoising methods within each ROI (NAWM, NEL, CEL).
3. Results

3.1. Denoising effects on simulated data SNR

In the acquired data, peak dynamic SNRs were 22.7 ± 14.8 [6.7, 59.0] (mean ± standard deviation [min, max], all 14 datasets) for lactate and 8.0 ± 4.1 [4.1, 18.0] for bicarbonate. Using a Gaussian distribution with standard deviation set to 1.25, the peak dynamic SNRs for the noise-added lactate signal were 6.7 ± 2.3 [4.0, 10.6]. The noise-added datasets better matched SNR levels of the acquired bicarbonate data (p-value > 0.05). After denoising, the SNRs were increased to 22.7 ± 14.8 [6.7, 59.1] (noise-added + TRI) and 30.0 ± 16.1 [8.8, 64.7] (noise-added + GL-HOSVD). The noise levels, as estimated from the background voxels of dynamic datasets, decreased significantly after denoising (p-value < 0.001), with the standard deviation of the background voxels being 1.5 ± 0.7 [1.2, 3.7] before denoising and 0.5 ± 0.3 [0.3, 1.6] (TRI) and 0.3 ± 0.3 [0.1, 1.3] (GL-HOSVD) following denoising. Denoising reduced noise levels below that of the acquired lactate signal, 0.5 ± 0.9 [0.1, 3.8]. The two methods performed comparably in terms of noise reduction (p-value > 0.05). An example of the acquired lactate signal, noise-added lactate, denoised, and acquired bicarbonate metabolite data is shown in Fig. 1.

An example of SNR masks before and after denoising compared to the mask of the acquired signal is shown in Fig. 2. A. Fig. 2B–2D demonstrate %N\textsubscript{lactate}, dice scores, and MSE values from all the subjects within each ROI. After applying denoising, %N\textsubscript{lactate} within the entire brain was significantly increased compared to the noise-added signals (TRI: p-value < 0.0001, GL-HOSVD: p-value < 0.0001) and comparable
to the acquired signal for both methods (\(p > 0.05\)). Dice scores of SNR masks within the brain increased from 0.2 ± 0.3 [0.0, 0.9] (noise-added) to 0.9 ± 0.2 [0.3, 1] (noise-added + TRI) and 0.9 ± 0.1 [0.6, 1.0] (noise-added + GL-HOSVD, respectively). MSE values for dynamic traces within the brain were lowered from 1.9 ± 1.2 [1.5, 6.4] (noise-added) to 1.1 ± 2.6 [0.2, 10.3] (noise-added + TRI) and 0.7 ± 1.7 [0.1, 7.0] (noise-added + GL-HOSVD, respectively). Compared to TRI, GL-HOSVD denoising recovered the acquired dynamic lac-tate signal values with better accuracy within the brain for each ROI; however, the performance of the two was comparable over the entire brain (comparing noise-added + TRI and noise-added + GL-HOSVD dice scores and MSE values, \(p > 0.05\)).

3.2. Denoising effects on kinetic modeling in simulated data

An example histogram of \(k_{PL}\) modeling error for data from Patient 14 is shown in Fig. 3A. The noise-added signal produces higher errors when compared to the acquired signal and subsequent denoising shifts the distribution of errors back towards that of the acquired distribution.

Across all patients, the coverage \(\%N_{PB}\), dice scores, and MSE values of \(k_{PL}\) within each ROI are shown in Fig. 3B-3D. Following denoising, \(\%N_{PB}\) within the brain increased significantly compared to the noise-added signals (\(p < 0.005\) for TRI, GL-HOSVD) while being comparable to the acquired coverages (\(p > 0.05\) for TRI, GL-HOSVD). Dice scores of \(k_{PB}\) modeling error masks within the brain increased significantly from 0.1 ± 0.2 [0.0, 0.8] (noise-added) to 0.6 ± 0.2 [0.2, 0.91] (noise-added + TRI, \(p < 0.0005\)) and 0.6 ± 0.3 [0.0, 1.0] (noise-added + GL-HOSVD, \(p < 0.0005\)). MSE values for \(k_{PB}\) values compared to acquired data \(k_{PB}\) within the brain were reduced from 1.2 ± 2.3 [0.8, 8.8] \(\times 10^{-4}\) (noise-added) to 0.6 ± 0.9 [0.09, 3.4] \(\times 10^{-4}\) (noise-added + TRI, \(p > 0.05\)) and 0.5 ± 0.8 [0.1, 3.3] \(\times 10^{-4}\) (noise-added + GL-HOSVD, \(p > 0.05\)).

The performances of the two were comparable (comparing noise-added + TRI and noise-added + GL-HOSVD dice scores and MSE values over the entire brain, \(p > 0.05\)). Across all patients, there was no significant difference in the mean \(k_{PB}\) values in NAWM voxels between any of the signals (acquired, noise-added, noise-added + TRI, and noise-added + GL-HOSVD; \(p > 0.05\) between all pairs).

It should be noted that for datasets with low SNR, acquired data had both a limited SNR mask and \(k_{PB}\) error mask, making simulated denoising results difficult to assess. For example, the acquired data for Patient 6 exhibited a particularly low \(\%N_{PB}\) of 0.5 % (2 voxels in the brain) and the dice score is 0.0 for GL-HOSVD. In such a case, comparisons between acquired and noise-added + denoised data were unreliable as the acquired data is not necessarily the ground truth. This is particularly true in the limited voxels of small lesion and is demonstrated by the large confidence intervals in Fig. 2(d) and 3(d).

3.3. Denoising effects on SNR for patient data

Denoising significantly reduced noise levels in all metabolites (\(p < 0.05\) for acquired vs TRI and GL-HOSVD both). Comparing TRI denoised and GL-HOSVD denoised noise levels showed GL-HOSVD provided significantly lower noise compared to TRI (\(p < 0.05\)) for pyruvate and bicarbonate data (\(p > 0.05\) for lactate signals). Fig. 4A shows the improvement in the peak dynamic SNR for each of the acquired metabolite signals following denoising for all datasets (ratio of peak dynamic SNR values following denoising to that of the acquired signal). GL-HOSVD provides significantly higher improvement in SNR for pyruvate and bicarbonate data compared to TRI (\(p < 0.0005\); \(p > 0.05\) for lactate data). Table 2 summarizes the improvement in peak dynamic SNRs within the whole brain for each metabolite (ratios of denoised SNRs to acquired SNRs). GL-HOSVD provided improvements up to a factor of 8 for \(^{13}\)C bicarbonate data, while TRI provided improvements up to a factor of 3. Fig. 4B-4D illustrate the \(\%N_{pyruvate}\), \%Nlactate, \%Nbicarbonate within each ROI for the acquired and denoised data. Although \%Nbicarbonate was improved significantly within the brain (TRI, \(p < 0.05\); GL-HOSVD, \(p < 0.005\)), the coverage remained limited within the CEL for all the patients. The two methods provide similar coverages for all metabolites across the entire brain (\(p > 0.05\)).

3.4. Denoising effects on kinetic modeling for patient data

An example of the \(k_{PB}\) and \(k_{PB}\) maps before and after applying GL-HOSVD denoising to all metabolite signals is shown in Fig. 5A. Although brain coverage of the \(k_{PB}\) map increased following denoising, the signal in the lesion remained low. This is indicative of a reduction in pyruvate-to-bicarbonate conversion in the lesion compared to the contralateral brain in this patient. The \(\%N_{PB}, \%N_{PB}\), \%Nlactate-to-pyruvate and \%Nbicarbonate-to-lactate within each ROI over all patient datasets are shown in Fig. 5B-5E. Averaged over all datasets, the voxel-wise average masked \(k_{PB}\) modeling error decreased from 23 % (acquired) to 16 % (TRI) and 15 % (GL-HOSVD). Similarly, \(k_{PB}\) modeling errors decreased from 42 % (acquired) to 34 % (TRI) and 37 % (GL-HOSVD). In the CEL, \(\%N_{PB}\) increased from about 48 % (acquired) of the ROIs to 84 % (TRI) and 90 % (GL-HOSVD). As with the \%Nbicarbonate, the \%Npyruvate and \%Nbicarbonate-to-lactate were not fully recovered in the CEL, with \%Nbicarbonate increasing from no coverage (0 %) to 15 % (TRI) and 8 % (GL-HOSVD) and \%Nbicarbonate-to-lactate increasing from no coverage (acquired) to 17 % (TRI) and 21 % (GL-HOSVD). Both methods significantly increased coverage over the entire brain (\(\%N_{PB}, \%N_{PB}\) %Npyruvate-to-
NeuroImage: Clinical 36 (2022) 103155

The two methods performed comparably in terms of number of voxels recovered over the entire brain (p-values > 0.05 for all). Across all patients, the mean $k_{PL}$ values in NAWM did not change significantly after denoising (TRI, p-value > 0.05; GL-HOSVD, p-value > 0.05). Comparison of mean modeled values are more challenging in lesions given limited number of voxels.

Table 2

Peak denoised metabolite SNR fold improvement in patient data. Fold improvement to the peak dynamic SNRs following denoising was calculated for each metabolite relative to the acquired data. Values are mean ± standard deviation [min, max] over all 14 datasets.

|                  | [1-13C]pyruvate | [1-13C]lactate | [13C]bicarbonate |
|------------------|-----------------|---------------|-----------------|
| TRI              | 2.3 ± 0.9 [1.3, 4.0] | 2.8 ± 1.1 [1.6, 5.7] | 2.4 ± 0.8 [1.3, 3.7] |
| GL-HOSVD         | 3.9 ± 0.8 [2.7, 5.3] | 3.1 ± 1.1 [1.9, 6.2] | 5.1 ± 2.2 [1.1, 7.9] |

The patients recruited for this study were at various clinical stages and thus analysis between the ROIs was not performed across patients. Examples of GL-HOSVD denoised data from a patient acquired prior to receiving any treatment (Patient 14), a patient with recurrent stable disease (Patient 8), and a patient with recurrent progressive disease.
(Patient 2) are illustrated in Figs. 6–8. All three patients had significant reductions in $k_{PB}$ and bicarbonate-to-lactate within the NEL compared to the NAWM. Increased $k_{PL}$ values were observed in the CEL of the recurrent patient with the progressive disease, while the %N bicarbonate and %N bicarbonate-to-lactate values are limited in the CEL. In contrast, the bicarbonate signals are quantifiable within the CEL in the recurrent patient with stable disease.

4. Discussion

This study evaluated the ability of TRI and GL-HOSVD to improve the quantification of HP-$^{13}$C signals acquired from patients with glioma. Denoising ability was assessed using SNRs (peak dynamic SNRs and voxel-wise aSNRs) and kinetic modeling errors on patient datasets with and without additional simulated noises. While both methods improved metabolite SNR and coverages, GL-HOSVD provided an advantage over...
TRI on voxel-wise peak dynamic SNR, metabolite coverages, and $k_{PL}$ and $k_{PB}$ coverages in many cases.

Image denoising often poses a trade-off between SNR improvements and loss of spatial and temporal delineation. The denoising methods evaluated in this work rely on the inherent compressibility of images to remove noise components via HOSVD. TRI denoising uses a pre-selected rank and imposes a trade-off between SNR improvements and over-truncation of the HOSVD core matrix. The latter could result in blurring artifacts, requiring more attention for selecting the rank of the spatial dimensions. Given the high compressibility of HP-13C MRI in the dynamic dimension, a small temporal rank was selected to provide more conservative noise removal that maintained voxel-wise differences.

**Fig. 7. Example of denoised data from a patient with recurrent, progressive disease.** A representative slice of $^1$H images and HP $^{13}$C EPI (overlaid on the axial T1 post-Gd image and linearly interpolated in-plane to $^1$H resolution) acquired from a patient with a recurrent glioblastoma are shown (Patient 2). Patient was scanned at the time of disease progression. The $k_{PL}$, $k_{PB}$, and bicarbonate-to-lactate values within each ROI (NAWM, NEL, CEL) are shown in the boxplots following 2x in-plane interpolation of GL-HOSVD denoised metabolites signals. The $k_{PL}$ values within the CEL were significantly higher compared to NAWM ($p = 0.019$), while $k_{PB}$ was significantly reduced. $k_{PB}$ ($p = 0.026$) and bicarbonate-to-lactate ($p = 0.0003$) within the NEL were also reduced compared to NAWM.

**Fig. 8. Example of denoised data from a recurrent patient with stable disease.** A representative slice of $^1$H images and HP $^{13}$C EPI images (overlaid on the axial T1 post-Gd image and linearly interpolated in-plane to $^1$H resolution) acquired from a patient with a recurrent glioblastoma are shown (Patient 8). No significant difference was found between the $k_{PL}$ values within the CEL or NEL compared to NAWM in this patient, while $k_{PB}$ within the NEL and bicarbonate-to-lactate within the CEL were reduced compared to NAWM ($p = 0.025$).
which are critical in the analysis of aberrant metabolism. Although a fixed tensor rank was used, it is important to visually inspect results for artifacts and structural similarity between the original and denoised images. Inspection of the singular values of the core tensor can also help with rank selection. As with TRI, $k_{\text{global}}$ and $k_{\text{local}}$ parameters in GL-HOSVD, which affect the level of smoothing observed in the final images, may need to be adjusted after visually assessing smoothing artifacts. In this work, $k_{\text{global}}$ and $k_{\text{local}}$ were first optimized using the noise-added lactate datasets to produce the lowest dynamic lactate MSE. Smoothing artifacts in both the denoised dynamic images and denoised AUC images were found to be sensitive to higher $k_{\text{local}}$ Values. Thus, this parameter was reduced to ameliorate smoothing artifacts and accordingly produced conservative improvements in SNR.

One important prerequisite to using the HOSVD denoising methods is the presence of Gaussian noise. Thus, such methods may not be directly applicable to magnitude MR images that contain Rician noise (Gudbjartsson and Patz, 1995). As described previously (Kim et al., 2021), denoising was applied to the real part of phased dynamic images, which exhibited characteristics of Gaussian noise. Due to the lack of ground truth and benchmark data in evaluating denoising techniques for dynamic $^{13}$C-MRI patient datasets, we used voxel-wise modeling errors based on the least-squares confidence intervals to evaluate denoising performance on the ability to recover estimated $k_{\text{bicarb}}$ and $k_{\text{bicarb}}$ values. Given the model’s assumption of Gaussian noise, these denoising methods are expected to reduce such fitting errors. However, kinetic modeling performed under assumptions of other noise characteristics may require more conservative noise removal to avoid introducing any modeling biases. A number of machine-learning based approaches have been introduced for denoising $^{1}$H MRSI data (Hatami et al., 2018; Lam et al., 2020; Lei et al., 2021). These methods rely on high-quality datasets and are not currently applicable to HP-$^{13}$C studies. In the future, as more datasets become available, such techniques for signal enhancement may confer reliable improvements to dynamic HP-$^{13}$C data post-processing.

Of particular interest in this study was the signal enhancement achieved with respect to $^{13}$Cbicarbonate in normal appearing brain tissue and tumor lesions. Because the real part of phase-corrected dynamic HP-$^{13}$C signals exhibit Gaussian noise (Kim et al., 2021), simulation experiments were performed by adding Gaussian noise to the acquired phased dynamic $^{13}$Clactate signal. The artificially reduced lactate SNR resulted in signal quality comparable to that of the acquired bicarbonate data. Because there is no inherently high-SNR bicarbonate data in patients, the noise-added lactate data served as a proxy to evaluate the performance of bicarbonate denoising. Using GL-HOSVD, the peak dynamic SNR of $^{13}$Cbicarbonate signals in patient data were improved as much as 8-fold. Despite this boost in SNR, the number of voxels within the CEL with aSNR greater than 5 remained limited. Similarly, the number of voxels in the CEL with sufficiently low $k_{\text{bicarb}}$ modeling error was few in each dataset. Given the ability of GL-HOSVD to recover lactate signal in the CEL when the data were artificially obscured by noise, these results support that known metabolic reprogramming (Warburg effects) results in increased conversion of pyruvate to lactate rather than to bicarbonate in active tumor.

The increased coverage following GL-HOSVD denoising allowed for voxel-wise regional analysis of metabolic differences, although this was not the focus of the study. The 3 patients shown in Figs. 6-8 had a significant reduction in the conversion from pyruvate to bicarbonate within the tumor compared to NAWM. In addition, the patient with progressive disease (Fig. 7, Patient 2) exhibited significantly higher $k_{\text{bicarb}}$ values within the CEL compared to NAWM, while this was not seen in the patient with clinically stable disease (Fig. 8). This is consistent with our previous findings in progressive patients (Autry et al., 2020a). Additionally, the bicarbonate signal was not quantifiable in the CEL of the recurrent patient with progressive disease, which may be indicative of a reduction in the conversion from pyruvate to bicarbonate in the active tumor. It is important to note, however, that treatment-induced changes may also contribute to observed metabolic differences. Further investigation of region-wide differences in HP-$^{13}$C parameters is needed in a larger set of patients to account for tumor heterogeneity, variations in treatment, and the different clinical stages at the time of the scan.

5. Conclusion

The ability of TRI and GL-HOSVD denoising methods to improve signal quality were evaluated on dynamic HP-$^{13}$C MRI data acquired from patients with glioma. Both methods improved the SNRs for acquired metabolite data as well as quantified $k_{\text{bicarb}}$ and $k_{\text{bicarb}}$ maps, with GL-HOSVD providing more of an increase in SNR than TRI. Although simulations show both post-processing HOSVD methods can recover artificially low-SNR dynamic metabolite images, the bicarbonate signal within the tumor lesion remains notably low after denoising, indicating increased pyruvate conversion to lactate through LDH and reduced PDH catalyzed conversion to CO$_2$/bicarbonate.

CRediT authorship contribution statement

Sana Vaziri: Conceptualization, Formal analysis, Methodology, Writing – original draft. Adam W. Autry: Conceptualization, Methodology, Writing – review & editing. Marisa Lafontaine: Writing – review & editing. Yaewon Kim: Methodology, Writing – review & editing. Jeremy W. Gordon: Conceptualization, Methodology, Writing – review & editing. Hsin-Yu Chen: Methodology, Writing – review & editing. Jasmine Y. Hu: Writing – review & editing. Janine M. Lupo: Conceptualization, Funding acquisition, Writing – review & editing. Susan M. Chang: Conceptualization, Funding acquisition, Writing – review & editing. Jennifer L. Clarke: Conceptualization, Funding acquisition, Writing – review & editing. Nancy Ann Oberheim Bush: Writing – review & editing. Duan Xu: Conceptualization, Funding acquisition, Writing – review & editing. Peder E.Z. Larson: Conceptualization, Methodology, Writing – review & editing. Daniel B. Vigneron: Conceptualization, Funding acquisition, Writing – review & editing. Yan Li: Conceptualization, Funding acquisition, Supervision, Writing – review & editing.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability

Data will be made available on request.

Acknowledgements

This project was supported by NIH T32 CA151022, R01 CA262630, P01 CA118816, P41EB013598, P50 CA097257, Department of Defense W81XWH2010292, and the Glioblastoma Precision Medicine Program.

References

Ardekijær-Larsen, J.H., Fridlund, B., Gram, A., Hansson, G., Hansson, L., Lerche, M.H., Servin, R., Thaning, M., Golman, K., 2003. Increase in signal-to-noise ratio of $>$ 10,000 times in liquid-state NMR. Proc. Natl. Acad. Sci. USA 100, 10158–10163.
Autry, A.W., Gordon, J.W., Carvajal, L., Mareyam, A., Chen, H.-Y., Park, I., mamma, D., Vareth, M., Chang, S.M., Wald, L.L., Xu, D., Vigneron, D.B., Nelson, S.J., Li, Y., 2019. Comparison between 8- and 32-channel phased-array receive coils for in vivo hyperpolarized (13) C imaging of the human brain. Magn. Reson. Med. 82 (2), 833–841.
Autry, A., Gordon, J., Lafontaine, M., Chen, H.Y., Villanueva-Meyer, J., Chang, S., Clarke, J.L., Xu, D., Lupo, J.M., Larson, P.E., Vigneron, D.B., Li, Y., 2020a. Initial...
